Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

Mixed-factorial analysis of variance with random-coefficient general linear model was used to compare their trends over time and linear multivariable regression was performed with a backward selection method to assess predictors of their variations from baseline to week 48.

Why It Was Studied

There is a paucity of prospective evaluations of bone markers after the initiation of drugs currently recommended to treat HIV infection and results on the evolution of these markers are conflicting.

Lastly, the effect of tenofovir on 1,25-(OH)₂ vitamin D is uncertain.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The researchers performed a prospective study on the evolution of bone markers, parathormone and 1,25-(OH)₂ vitamin D before and after standard antiretroviral regimens.

This was a sub-study of a trial conducted in antiretroviral-naïve patients randomized to tenofovir + emtricitabine in combination with either atazanavir/ritonavir (ATV/r) or efavirenz (EFV).

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The following bone markers were analyzed: C-terminal cross-laps (CTx), osteocalcin (OC), osteoprotegerin (OPG), and receptor activator of nuclear factor κB ligand (RANKL).

Trends of parathormone and 1,25-(OH)₂ vitamin D were also evaluated.

What Was Measured

There is a paucity of prospective evaluations of bone markers after the initiation of drugs currently recommended to treat HIV infection and results on the evolution of these markers are conflicting.

Topics PubMed links to this paper include Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Biomarkers, Bone and Bones, Ergocalciferols, HIV Infections and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized study of Parathyroid Hormone (PTH 1-84).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (BMC infectious diseases), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.